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TransfusionBackground: Recently, chronic hepatitis E has been increasingly reported in organ transplant recipients in
European countries. In Japan, the prevalence of hepatitis E virus (HEV) infection after transplantation remains
unclear, so we conducted a nationwide cross-sectional study to clarify the prevalence of chronic HEV infection
in Japanese liver transplant recipients.
Methods:A total of 1893 liver transplant recipients in 17university hospitals in Japanwere examined for the pres-
ence of immunoglobulin G (IgG), IgM and IgA classes of anti-HEV antibodies, and HEV RNA in serum.
Findings: The prevalence of anti-HEV IgG, IgM and IgA class antibodies was 2.9% (54/1893), 0.05% (1/1893) and
0% (0/1893), respectively. Of 1651 patients tested for HEV RNA, two patients (0.12%) were found to be positive
and developed chronic infection after liver transplantation. In both cases, HEV RNA was also detected in one of
the blood products transfused at the perioperative period. Analysis of the HEV genomes revealed that the HEV
isolates obtained from the recipients and the transfused blood products were identical in both cases, indicating
transfusion-transmitted HEV infection.hchi).
. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1608 Y. Inagaki et al. / EBioMedicine 2 (2015) 1607–1612Interpretation: The prevalence of HEV antibodies in liver transplant recipients was 2.9%, which is low compared
with the healthy population in Japan and with organ transplant recipients in European countries; however, the
present study found, for the ﬁrst time, two Japanese patients with chronic HEV infection that was acquired via
blood transfusion during or after liver transplantation.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hepatitis E is caused by infection with the hepatitis E virus (HEV),
and HEV isolates that infect humans are currently categorized into four
genotypes (1–4) (Okamoto, 2007). Genotypes 1 and 2 are restricted to
humans and mainly waterborne transmitted in developing countries.
In contrast, genotypes 3 and 4 are known to undergo zoonotic transmis-
sion by consumption of uncooked or undercookedmeat or viscera of res-
ervoir mammals and autochthonous isolates cause sporadic infections in
industrialized countries (Takahashi et al., 2003; Tei et al., 2003).
Acute hepatitis E varies in severity from inapparent to fulminant.
Mortality has been reported to be between 1% and 4% in the general
population but up to 25% in pregnant women (Datta et al., 1987). HEV
infection has traditionally been considered to be a transient and self-
limiting disease requiring no speciﬁc therapy in immunocompetent
individuals (Wedemeyer et al., 2012). However, HEV infection may oc-
casionally cause severe liver dysfunction, fulminant hepatitis, and liver
failure in some patients with an underlying disease (Kamar et al.,
2012; Suzuki et al., 2002). Furthermore, HEV genotype 3 can lead to
chronic hepatitis and liver cirrhosis in immunocompromised patients
such as solid-organ transplant (SOT) recipients (Kamar et al., 2008), pa-
tients with human immunodeﬁciency virus infection (Dalton et al.,
2009), and patients with hematologic cancers receiving chemotherapy
(Ollier et al., 2009). Various studies have investigated the presence of
HEV infection in SOT recipients in European and American countries
but not yet in Japan.We conducted the ﬁrst nationwide survey to clarify
the prevalence of HEV antibodies and the presence of liver transplant
recipients with chronic HEV infection in Japan.
2. Methods
2.1. Study Subjects
From all the regions of Japan, 17 high-volume centers for liver trans-
plantation participated in this study (from north to south): Hokkaido
University Hospital in Hokkaido; Tohoku University Hospital in the
Tohoku area; University of Tsukuba Hospital, University of Tokyo
Hospital, Keio University Hospital and Juntendo University Hospital in
the Kanto area; Shinshu University Hospital in the Chubu area; Kyoto
University Hospital, Osaka University Hospital and Kobe University
Hospital in the Kinki area; Okayama University Hospital and Hiroshima
University Hospital in the Chugoku area; EhimeUniversity Hospital and
TokushimaUniversity Hospital in the Shikoku area; and KyushuUniver-
sity Hospital, Nagasaki University Hospital and Kumamoto University
Hospital in the Kyushu area. The number of liver transplantations per-
formed in these 17 centers accounts for approximately 75% of the total
performed in Japan (The Japanese Liver Transplantation Society, 2014).
Between April 1, 2013 and December 31, 2014, blood samples were
collected from 1893 recipients being followed up at the above-
mentioned 17 centers after liver transplantation. Anti-HEV antibodies
were tested for in all 1893 samples. Within all the 1893 participants,
1651 patients who agreed to have HEV RNA testing, including all pa-
tients with detectable anti-HEV Ig (immunoglobulin) G class antibody,
were also tested for the presence of HEV RNA in serum. The samples
were stored at−80 °C until testing. The clinical data of the patients, in-
cluding medical history, medication proﬁles and laboratory test results,
were retrieved from medical records. This study was approved by theinstitutional reviewboard at every participating hospital and performed
in accordancewith the Declaration of Helsinki and ethical guidelines for
clinical research. All the patients gave written informed consent to par-
ticipate in this study.
2.2. Detection of Anti-HEV Antibodies and HEV RNA
To detect anti-HEV IgA, IgM and IgG class antibodies, in-house
enzyme-linked immunosorbent assay (ELISA) was performed using pu-
riﬁed recombinant ORF2 protein as described previously (Mizuo et al.,
2002). The optical density (OD) of each sample was read at 450 nm.
The cut-off value used for anti-HEV IgA, IgM and IgG was 0.642, 0.440
and 0.175, respectively (Takahashi et al., 2005). The samples with OD
values for anti-HEV IgA, IgM, or IgG equal to or greater than the respec-
tive cut-off value were considered to be positive for each antibody. The
speciﬁcity of ELISAwas validated by absorptionwith the same recombi-
nant ORF2 protein that was used as the antigen probe, as described pre-
viously (Takahashi et al., 2005).
Total RNA was extracted from 100 μL of each serum or whole blood
sample and subjected to nested reverse transcription-polymerase chain
reaction (RT-PCR) for the detection of HEV RNA. A nested RT-PCR
targeting the 137-nt ORF2/3 overlapping region was conducted for the
screening of HEV RNA (Inoue et al., 2006). This method represents a
high sensitivity and is able to detect 1–3 copies of HEV RNA in 100 μL
serum. For the samples detected positive by theORF2/3–137 PCR,we per-
formed an additional nested RT-PCR targeting the 457-nt ORF2 region to
conﬁrm the presence of HEV RNA and to assess the subgenotype, as de-
scribed previously (Mizuo et al., 2002). The HEV genotype/subgenotype
was determined based on the phylogenetic analysis of theORF2 sequence.
Quantitation of HEV RNA was performed by real-time detection RT-
PCR as described previously (Takahashi et al., 2008).
3. Results
3.1. Characteristics of the Subjects
A total of 1893 liver transplant recipients participated in this study;
their demographic characteristics and laboratory data are presented in
Table 1. Median agewas 57 years old andmedian time since liver trans-
plantation to serum samplingwas 81months. At the time of blood sam-
pling, the median values of aspartate aminotransferase (AST), alanine
aminotransferase (ALT), total bilirubin (T-Bil) and gamma-glutamyl
transferase (γ-GT) were exclusively within normal limits. “Liver injury
episode after transplantation” was deﬁned as the presence of elevated
liver enzymes acquiring the management with re-hospitalization, and
61.3% of the recipients were included.
3.2. Prevalence of Anti-HEV Antibodies and HEV RNA
All of the 1893 serum sampleswere subjected to ELISA for the detec-
tion of anti-HEV antibodies (Table 2). Fifty-four patients (2.9%) were
found to be positive for anti-HEV IgG class antibody. The age- and sex-
speciﬁc prevalence of IgG class antibody in the recipients is shown in
Fig. 1. The prevalence was slightly higher among the males (3.3%)
than among the females (2.4%), although not statistically signiﬁcant,
and generally increased with age. Only one patient with detectable
IgG class antibody was also positive for IgM class antibody (0.05%),
Table 1
Characteristics of liver transplant recipients.a
Total number of recipients [n] 1893
Age [years; median (total range)] 57 (0–83)
Sex [n (%); male/female] 970 (51.2)/923 (48.8)
Time from transplantation
[months; median (total range)]
81 (0–297)
Laboratory data at sampling
WBC [/μL; median (total range)] 5565 (1070–97,000)
Lymphocyte [/μL; median (total range)] 1576 (157–24,225)
AST [IU/L; median (total range)] 24 (1–484)
ALT [IU/L; median (total range)] 19 (3–619)
T-Bil [mg/dL; median (total range)] 0.8 (0.1–40.0)
γ-GT [IU/L; median (total range)] 36 (0–3118)
Immunosuppression [n (%)]
Tacrolimus/cyclosporin 1359 (71.8)/327 (17.3)
Mycophenolic acid 685 (36.2)
Corticosteroids 681 (36.0)
Re-hospitalization due to liver injury
episode after transplantationa [n (%)]
1161 (61.3)
Note: WBC, white blood cell; AST, aspartate aminotransferase; ALT, alanine aminotrans-
ferase; T-Bil, total bilirubin; γ-GT, gamma-glutamyl transferase.
a Liver injury episode after transplantationwas deﬁned as the presence of elevated liver
enzymes acquiring the management with re-hospitalization.
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positive for IgG and IgM antibodies, HEV RNA was also detectable as
noted below.
Two of the 54 patients with anti-HEV IgG tested positive for HEV
RNA, while none of the remaining 1597 patients without detectable
IgG class antibody who agreed to have the HEV RNA testing were posi-
tive forHEVRNA. Overall, HEVRNAwas found to be positive at the prev-
alence rate of 0.12% (2/1651) (Table 2). The detailed clinical information
and laboratory data at the time of diagnosis in these two HEV RNA-
positive patients are shown in Table 3. Case 1 patient was a 60-year-
old female living in the Kanto area who received liver transplantation
for primary sclerosing cholangitis, while Case 2 patient was a 41-year-
old male living in the Kyushu area who received liver transplantation
for non-alcoholic steatohepatitis complicated with hepatocellular carci-
noma. In these two patients, the duration from liver transplantation to
blood sampling was lower than the 25 percentile (36 months), and
the peripheral blood lymphocyte count was lower than the 25 percen-
tile (1039 /μL). Whereas 71.8% and 35.9% of the patients negative for
HEV RNA had been taking tacrolimus and corticosteroids respectively,
both two positive patients had been taking tacrolimus and corticoste-
roids for immunosuppression. The HEV isolates were typed as genotype
3 in both patients (Table 3). The more detailed clinical courses of these
two patients will be described elsewhere.
3.3. Elucidation of Possible Infectious Source and Route
To clarify whether these two HEV-viremic patients contracted HEV
infection during or after liver transplantation and to investigate the pos-
sible infectious route of HEV in these patients, we retrospectively tested
anti-HEV antibodies and HEV RNA in stored serum samples from each
pair of patient and liver donor (Table 4).
In Case 1 patient, anti-HEV IgG class antibody was weakly positive;
representing past HEV infection, while HEV RNA was not detected in
the pre-transplant serum. Anti-HEV IgG became high-titer positiveTable 2
Prevalence of HEV antibodies and HEV RNA in liver transplant recipients.a
Positive patient [n] Percent [%]
Anti-HEV IgG 54/1893 2.9
Anti-HEV IgM 1/1893 0.05
Anti-HEV IgA 0/1893 0
HEV RNA 2/1651a 0.12
Note: Ig, immunoglobulin.
a The number of patients whose informed consent for testing HEV RNA was available.(OD value: N3.000) on the 255th postoperative day (POD) accompanied
by high-titer HEV RNA (8.1 × 105 copies/mL), and HEV RNAwas persis-
tently positive on the 360th POD. In Case 2 patient, anti-HEV IgG and
IgM antibodies and HEV RNA were negative in the pre-transplant
serum. On the 81st POD, the positive conversion of IgG and IgM
antibodies was detected accompanied by high-titer HEV RNA
(1.3 × 106 copies/mL). HEV RNA was persistently positive on the
249th POD. These results suggested that both patients acquired their
HEV infection during or after liver transplantation and developed
chronic infection of HEV. In addition, retrospective and prospective in-
vestigation of their laboratory data and virological analysis revealed
that these recipients had presented mild liver injury and HEV viremia
for at least more than 6 months. Therefore, these two patients were
ﬁnally diagnosed as having chronic hepatitis E.
In both cases, HEV antibodies andHEVRNAwere undetectable in the
liver donors, excluding the possibility of de novo HEV infection from the
transplanted liver. The two HEV-viremic patients had no history of eat-
ing raw or undercooked meat or shellﬁsh after liver transplantation.
During the perioperative period of liver transplantation, a total of 17
units of blood products (concentrated red blood cells, fresh frozen plas-
ma or platelets) were transfused in Case 1 patient, and 26 units of blood
products (concentrated red blood cells, fresh frozen plasma or platelets)
transfused in Case 2 patient. Pilots of all the blood products transfused
during the perioperative period had been stored in the Japanese Red
Cross Society, and were also tested for the presence of HEV RNA. HEV
RNA was detectable in one unit of the fresh frozen plasma transfused
to Case 1 patient (the viral titer was not available) and one unit of the
platelet preparation transfused to Case 2 patient (the viral titer was
1.8 × 104 copies/mL). Complete nucleotide sequence identity was ob-
tained in the 412-nt sequence of ORF2 of each HEV isolate. As a result,
in both cases, the HEV isolates detected from the recipient and the
blood product were considered to be same, and the transfused blood
products were determined to be the infectious source.
4. Discussion
HEV infection had not been considered responsible for chronic hep-
atitis until Kamar et al. reported the ﬁrst case series of chronic hepatitis
E in SOT recipients in 2008 (Kamar et al., 2008). Subsequently, chronic
infections of HEV in transplant recipients have been described in several
studies (Haagsma et al., 2009; Legrand-Abravanel et al., 2010). Accord-
ing to the latest review article in 2014, up to 50–60% of acute HEV infec-
tions can progress to chronic phase in SOT recipients and HEV infection
can take rapid courses leading to liver cirrhosis in patients receiving im-
munosuppressants (Behrendt et al., 2014). Despite the high prevalence
of HEV in the SOT recipients in European countries, chronic hepatitis E
in Asian countries has been rarely reported (Behrendt et al., 2014).
By 2013, over 7000 liver transplants had been performed in Japan
(The Japanese Liver Transplantation Society, 2014). The number of na-
tional notiﬁcations of acute hepatitis E has been increasing since anti-
HEV IgA antibody measurement started to be covered by insurance in
2011 (The National Institute of Infectious Diseases. Infectious Diseases
Weekly Report (IDWR), 2003–2013), and the isolation of autochtho-
nousHEV as a causative agent of acute hepatitis has increased.However,
no nationwide survey of HEV infection in liver transplant recipients had
been performed. So the present study is the ﬁrst nationwide survey to
investigate the prevalence of HEV infection in liver transplant recipients
in Japan. This large multicenter severance clariﬁed that the presence of
HEV infection in liver transplant recipients is not frequent in Japan com-
pared with in Western countries as described below. However, two
cases of transfusion-transmitted hepatitis E were detected; therefore,
recipients have low but certain risk of HEV infection by blood products.
Thoughmore than 60% of the recipients had some kind of episode of
liver injury, the values of liver enzymes, T-Bil and γ-GTwere exclusively
within normal limits at the time of sampling. These episodes of liver in-
jury were most commonly due to the biliary complication or the
Fig. 1. The age- and sex-speciﬁc prevalence of anti-HEV IgG class antibody in liver transplant recipients in Japan. The overall prevalence of anti-HEV IgG class antibody in liver transplant
recipients was 2.9% (male, 3.3%; female, 2.4%). The prevalence generally increased with age.. n: the number of the recipients in each age group.
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In addition, even in the ongoing HEV infection cases, liver dysfunction
was not severe or within normal limit sometimes. These laboratory
data ﬂuctuates easily in liver transplant recipients and it should be dif-
ﬁcult to suspect active HEV infection from the clinical features alone.
In recent years, the prevalence and clinical courses of hepatitis E in
transplant recipients were reported in European countries, North
America and Iran (Legrand-Abravanel et al., 2010; Halac et al., 2012).
In a review by Zhou et al. (2013), the overall prevalence of anti-HEV
IgG class antibody in SOT recipients was 11.6% and 7.4% in liver trans-
plant recipients. This review article included the results detected by
several different ELISA kit, and different commercial serological mea-
surements are known to indicate a variability of the prevalence rate
(Kamar et al., 2012). Khan et al. (2011) analyzed the sensitivity and
speciﬁcity of four ELISA systems for HEV antibodies (Abbott, Cosmic,
TGH and Wantai) and revealed that Wantai test had the highest sensi-
tivity and speciﬁcity (100% and 100%, respectively) among them. In
this report, Cosmic test using our ELISA system also showed high sensi-
tivity and speciﬁcity (98.1% and 100%, respectively) following Wantai
test. Although it is difﬁcult to compare, of course, the prevalence of
IgG antibody in our study (2.9%) was lower than these reviewed preva-
lence rates. This is due to the intrinsic lower prevalence of HEV in theTable 3
Characteristics of HEV RNA-positive liver transplant recipients.
Variables Case 1 Case 2
Age [years], sex 60, female 41, male
Living area Kanto Kyushu
Primary disease Primary sclerosing
cholangitis
Non-alcoholic
steatohepatitis,
hepatocellular
carcinoma
Time from transplantation [months] 8 3
Laboratory data at sampling
WBC [/μL] 1500 6170
Lymphocyte [/μL] 453 882
AST [IU/L] 23 36
ALT [IU/L] 27 48
T-Bil [mg/dL] 0.8 0.4
γ-GT [IU/L] 81 63
Immunosuppression Tacrolimus,
corticosteroids
Tacrolimus,
corticosteroids
Liver injury episode
after transplantation
+ +
HEV genotype 3 3general population in Japan compared with in European countries
(Kamar et al., 2012; Takahashi et al., 2010a). The prevalence in liver
transplant recipients in Japan was also lower than 5.1% in Japanese
blood donors whose age was 40–59 years old, and the male rate was
50% (Takeda et al., 2010). We have reported the prevalence of healthy
people (Takahashi et al., 2010a), blood donors (Gotanda et al., 2007), di-
alysis patients (Mitsui et al., 2004) in Japan using the same ELISAmeth-
od in this study, and the prevalence of Japanese recipients is also lower
than these previous results. The low prevalence in the recipients is not
thought to arise from the sensitivity of the measurement but from the
special characteristics of the patients in this study.
The conceivable causes of the lower prevalence in the transplant re-
cipients are as follows: First, it is possible that the reduction of the anti-
HEV antibody titers was induced by immunosuppressive drugs (Sester
et al., 2008). Second, avoiding consumption of raw or undercooked
meat or shellﬁsh after transplantation might reduce the chance of HEV
infection, as normally seen in the general population. At 11 of the 17 in-
stitutions in this survey, the liver transplant recipients were prohibited
from consuming raw or undercooked foods for at least 6 months after
transplantation. Unfortunately, the serum samples before transplanta-
tionwere not available from themajority of the studied patients, except
for those from Case 1 and 2 patients with HEV viremia, and the preva-
lence of antibodies before and after transplantation could not be com-
pared. However, on the basis of the assumption that half of acute HEV
infections progress to chronic phase in transplant recipients (Behrendt
et al., 2014), the liver transplant patients in Japan had less opportunity
to be infected. In the two of HEV infection cases, IgA antibodies were
not detected throughout the following course. Although anti-HEV IgA
antibody measurement is covered by insurance in Japan because of its
high sensitivity and speciﬁcity (Takahashi et al., 2005), HEV RNA detec-
tion seems to be themost suitable to detect the chronic infection in im-
munocompromised patients. The methods used in this study present a
sufﬁcient sensitivity and the low presence of ongoing HEV infection is
likely to be true.
HEV infection is usually self-limiting in immunocompetent individ-
uals and therefore speciﬁc therapies are not required in the majority
of cases. However, it can lead to chronic hepatitis and liver cirrhosis in
patients taking immunosuppressants after organ transplantation.
Haagsma et al. (2009) reported two cases of liver transplantation in
which chronic HEV infection developed gradually into graft cirrhosis
and a second transplantation was needed. To prevent graft failure,
persistent HEV infection in liver transplant recipients should not be
overlooked and untreated. The ﬁrst strategy for recipients with
Table 4
The behavior of anti-HEV antibodies and HEV RNA in the chronic infection cases.
Case 1 Case 2
Anti-HEV
IgG
[OD value]
Anti-HEV
IgM
[OD value]
Anti-HEV
IgA
[OD value]
HEV RNA
[copies/mL]
Anti-HEV
IgG
[OD value]
Anti-HEV
IgM
[OD value]
Anti-HEV
IgA
[OD value]
HEV RNA
[copies/mL]
Pre-transplantation 0.410 (+) 0.041 (−) 0.062 (−) – Pre-transplantation 0.016 (−) 0.051 (−) 0.197 (−) –
At diagnosis
(255 POD)
N3.000 (+) 0.223 (−) 0.089 (−) 8.1 × 105
At diagnosis
(81 POD)
0.204 (+) 1.063 (+) 0.082 (−) 1.3 × 106
After diagnosis
(360 POD)
N3.000 (+) 0.203 (−) 0.105 (−) 5.5 × 104
After diagnosis
(249 POD)
N3.000 (+) 1.480 (+) 0.143 (−) 3.2 × 106
Liver donor 0.021 (−) 0.029 (−) 0.021 (−) – Liver donor 0.006 (−) 0.036 (−) 0.010 (−) –
Blood donor
(FFP)
NA NA NA +a
Blood donor
(Platelet)
NA NA NA 1.8 × 104
Note: OD, optical density; POD, postoperative day; FFP, fresh frozen plasma; NA, not available.
a The titer of HEV RNA was not available.
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suppressants, the second strategy is considered to be anti-viral thera-
pies (Kamar et al., 2011). In our study, Case 1 patient had received
anti-viral therapy and Case 2 had been followed up without any anti-
viral therapy or reduction of the immunosuppressants after the diagno-
sis. More detailed information about the clinical courses of these cases
will be published in a short time.
A previous study on the risk factors in SOT recipients for developing
chronic hepatitis after acute HEV infection revealed that the recipients
who developed chronic hepatitis had signiﬁcantly lower counts of leu-
kocytes, total lymphocytes, platelets, and CD2, CD3, and CD4 lympho-
cytes than transient patients (Kamar et al., 2008). In the present study,
two caseswith chronic infectionwere exposed to HEV in the early post-
operative period and lower counts of lymphocytes in peripheral blood
were observed. The reduced production of antibodies due to high dose
immunosuppressants in the early postoperative period could contribute
to the development of chronic infection even in a patient previously ex-
posed to HEV. However, we cannot easily conclude from our results that
these are the factors for risk of a chronic career after acuteHEV infection,
because we could neither detect any transient hepatitis patient nor
compare the progress of acute and chronic infections.
HEV genotypes 3 and 4 usually cause sporadic infections, in industri-
alized countries most likely due to intake of contaminated food. HEV
RNA has been detected in a variety of food products, especially in por-
cine livers (Colson et al., 2010). However, HEV can also be transmitted
via the transplanted organ itself or through blood transfusion. Schlosser
et al. reported that HEV transmission via the infected donor liver lead to
chronic infection and graft cirrhosis development after liver transplan-
tation (Schlosser et al., 2012). Several previous case reports suggested
that HEV transmission by blood products is possible (Matsubayashi
et al., 2004;Wedemeyer et al., 2012). According to the newest epidemi-
ology of autochthones hepatitis E virus infection in Japan, 11 patients of
43 asymptomatic hepatitis E cases were detected from blood donors
(Kanayama et al., 2015). In another report, 2% of HEV infections are as-
cribable to blood transfusion in Japan (Abe et al., 2006). Recently,
Hewitt et al. reported that 42% of the patients in England transfused
with HEV-positive blood products had evidence of infection with HEV
and immunocompromised patients, including organ transplant recipi-
ents, showed prolonged viral infection (Hewitt et al., 2014). The two
patients reported in our present study were the ﬁrst cases with
transfusion-transmitted chronic hepatitis E in liver transplant recipients
in Japan, to the best of our knowledge. In addition, de novo HEV infec-
tion developed despite the presence of anti-HEV antibodies in Case 1.
Takahashi et al. reported that themajority of HEV virions in serum pos-
sess lipids on their surfaces and inhibit neutralization by antibodies
(Takahashi et al., 2010b). In Japan, screening of donated blood for HEV
has only been conducted in the Hokkaido area, where HEV infection is
most prevalent (Takahashi et al., 2010a). Patients receiving blood prod-
ucts include many immunocompromised individuals, so screening ofblood donors for HEV in other areas in Japan is probably desirable:
moreover, further investigations about HEV infection in other trans-
plant recipients and immunosuppressed patients are required.
5. Conclusions
This study is the ﬁrst multicenter survey for HEV infection in Asian
liver transplant recipients and the presence of HEV infection is low in
Japan; however, liver transplant recipients have a risk of transfusion-
transmitted chronic hepatitis E. HEV infection should be considered as
a differential diagnosis and molecular biological detection of HEV
should be essential, when the recipient receives blood products and
presents unknown liver injury.
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